Insider Activity: Dova Pharmaceuticals (DOVA)

  • Free: 7 High Yield Dividend Stocks to Buy Now
  • Major holder adds to stake in beaten-down biotech company.

  • Special: This Market is Growing at the Fastest Rate Since 2006
  • Insiders in the health, pharmaceutical, and biotech space continue to buy shares of their beaten-down companies near today’s prices.

    The latest big buy? At shares of one of the smaller biotech plays, Dova Pharmaceuticals (DOVA).

    • The Time to Invest in 5G Is NOW

      Happy Woman Holding Phone AT&T has just become the first carrier to offer 5G coverage.

      Sprint's 5G network is live in Phoenix, New York City, Washington, D.C., and Los Angeles.

      T-Mobile has flipped the 5G switch in six cities...

      And Verizon has launched its 5G network in 13 cities.

      Nearly a decade in the making, 5G is finally here...

      And just ONE stock is your No. 1 chance to profit from the 5G revolution.

      Details HERE...

    On July 3rd, the Perceptive Life Sciences Master Fund, which already owns more than 10 percent of shares and has a seat on the board of directors, added to their stake.

    The fund bought 20,541 shares, paying just under $300,000. But this isn’t their first buy with this company. They also bought shares on June 28th, that time picking up over 427,000 shares and increasing their stake by over $5.7 million.

  • Special: FREE – The 11 EV Stocks You Need in Your Arsenal
  • Founded in 2016, Dova is a pharmaceutical company focusing on acquiring and developing drug candidates specifically for thrombocytopenia disease. Shares have traded between $6 and $30 in the past year, and have recently started to rally, closing 9 percent higher on Wednesday just under $18 per share.

    Action to take now: With major shareholders adding to their stake, and with a 52-week high at $30, shares have plenty of room to run. As a smaller pharma play, there are fewer options trades available, making shares one of the more interesting bets in the market right now.